x
CME-Tagline

Live Q&A: Rethinking Routines in Multiple Sclerosis Management: What the Future Holds for DMTs and Cognitive Assessment Strategies

CMEO Webcast

Premiere Date: Wednesday, March 31, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, March 31, 2022

Faculty


Tanuja Chitnis, MD, FAAN Tanuja Chitnis, MD, FAAN 
Professor of Neurology, Harvard Medical School
Director, Partners Pediatric Multiple Sclerosis Center
Massachusetts General Hospital
Director, Translational Neuroimmunology Research Center
Director, Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) Study
Partners Multiple Sclerosis Center
Brigham and Women's Hospital
Boston, MA

Statement of Need

Cognitive impairment (CI) is common in patients with MS and contributes substantially to disability, loss of employment, and declines in quality of life, yet CI remains underrecognized. CI is increasingly being evaluated in clinical trials of MS therapies, and emerging evidence regarding cognitive effects of disease-modifying therapies (DMTs) and the relationship between CI and other features of MS progression may have important implications for MS management.

This live question and answer session is your opportunity to ask questions based on the CME Outfitters virtual symposium where expert faculty focused on the prognostic factors that should be considered when developing treatment plans for patient with MS, as well as the latest clinical data on approved and emerging DMTs.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply clinical data on efficacy and safety of recently approved therapies to individualized treatment decisions for patients with MS.
  • Incorporate cognitive assessment into routine monitoring for patients with MS.
  • Evaluate emerging data on the effects of MS therapies on cognition.

The following learning objectives pertain only to those requesting CNE credit:

  • Examine clinical data on efficacy and safety of recently approved therapies for individualized treatment plans for patients with MS.
  • Describe how to incorporate cognitive assessment into routine monitoring for patients with MS.
  • Evaluate emerging data on the effects of MS therapies on cognition.

Financial Support

Supported by an educational grant from Bristol-Myers Squibb Company

Target Audience

Neurologists, PAs, nurse practitioners, nurses, pharmacists, and other HCPs involved in care of patients with MS

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-21-057-L01-P

Type: knowledge-based

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chitnis has no disclosures to report.

Rachel Speer, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MMQ-110-033121-08